1.59 USD
▲+0.06+10.42%
盘后 1.45 +0.69%
2026-08-03
市值
$2.82M
市盈率
—
EPS
-27.02
股息率
—
52 周区间
1.36 – 80.36
成交量
45.42K
Beta
-0.66
目标价
21.00
52W 低 1.3652W 高 80.36
价格走势
公司简介
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells ...